Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
Add more filters










Database
Language
Publication year range
1.
Stem Cell Res ; 79: 103483, 2024 Jun 22.
Article in English | MEDLINE | ID: mdl-38943762

ABSTRACT

Recent studies reported that the mutation in the THAP11 gene (THAP11F80L) could be responsible for the inborn vitamin deficiency known as cobalamin disorder, by affecting the expression of the enzyme MMACHC, key in the cobalamin metabolism. However, the specifics of the molecular mechanism are largely unknown. In here we generated genetically modified human pluripotent stem cell lines with THAP11F80L mutation, providing a new research tool for futher exploring the molecular mechanism. The established hPSC lines remain pluripotent, showing expression of OCT3/4, differentiation capacity to the three germ layers and displaying normal karyotype.

2.
Drug Discov Today ; 25(2): 456-465, 2020 02.
Article in English | MEDLINE | ID: mdl-31783130

ABSTRACT

The paradigm of central nervous system (CNS) drug discovery has mostly relied on traditional approaches of rodent models or cell-based in vitro models. Owing to the issues of species differences between humans and rodents, it is difficult to correlate the robustness of data for neurodevelopmental studies. With advances in the stem-cell field, 3D CNS organoids have been developed and explored owing to their resemblance to the human brain architecture and functions. Further, CNS organoids provide a unique opportunity to mimic the human brain physiology and serve as a modeling tool to study the normal versus pathological brain or the elucidation of mechanisms of neurological disorders. Here, we discuss the recent application of a CNS organoid explored for neurodevelopment disease or a screening tool for CNS drug development.


Subject(s)
Brain , Central Nervous System Diseases , Drug Evaluation, Preclinical , Models, Biological , Neurotoxicity Syndromes , Organoids , Animals , Humans
3.
Drug Des Devel Ther ; 13: 3591-3605, 2019.
Article in English | MEDLINE | ID: mdl-31695329

ABSTRACT

The blood-brain barrier (BBB) is comprised of brain microvascular endothelial central nervous system (CNS) cells, which communicate with other CNS cells (astrocytes, pericytes) and behave according to the state of the CNS, by responding against pathological environments and modulating disease progression. The BBB plays a crucial role in maintaining homeostasis in the CNS by maintaining restricted transport of toxic or harmful molecules, transport of nutrients, and removal of metabolites from the brain. Neurological disorders, such as NeuroHIV, cerebral stroke, brain tumors, and other neurodegenerative diseases increase the permeability of the BBB. While on the other hand, semipermeable nature of BBB restricts the movement of bigger molecules i.e. drugs or proteins (>500 kDa) across it, leading to minimal bioavailability of drugs in the CNS. This poses the most significant shortcoming in the development of therapeutics for CNS neurodegenerative disorders. Although the complexity of the BBB (dynamic and adaptable barrier) affects approaches of CNS drug delivery and promotes disease progression, understanding the composition and functions of BBB provides a platform for novel innovative approaches towards drug delivery to CNS. The methodical and scientific interests in the physiology and pathology of the BBB led to the development and the advancement of numerous in vitro models of the BBB. This review discusses the fundamentals of BBB structure, permeation mechanisms, an overview of all the different in-vitro BBB models with their advantages and disadvantages, and rationale of selecting penetration prediction methods towards the critical role in the development of the CNS therapeutics.


Subject(s)
Blood-Brain Barrier/metabolism , Drug Delivery Systems , Pharmaceutical Preparations/administration & dosage , Biological Transport/physiology , Brain/metabolism , Central Nervous System/metabolism , Humans , Models, Biological , Permeability , Pharmaceutical Preparations/metabolism
4.
Semin Cancer Biol ; 57: 111-116, 2019 08.
Article in English | MEDLINE | ID: mdl-30213689

ABSTRACT

Prostate cancer is the most prevalent type of cancer in men. The etiology of prostate cancer development and the mechanisms underlying androgen-independent progression remains to be further investigated. There are many known targets for prostate cancer therapy including the androgen receptor (AR) axis, but resistance eventually develops in advanced disease suggesting the need to better understand mechanisms of resistance and consideration of multi-targeted therapy. Mechanisms contributing to resistance may include gene amplifications, gene mutations, AR splice variants, and changes in expression of androgen receptor co-regulatory proteins. Given the limitations of approved therapies, further study of additional potential targets is warranted. This review focuses on the roles of autophagy pathway, p62, Yes-associated protein (YAP), cancer stem cells, and epigenetics. Therapies targeting these potential mechanisms of resistance may interact with currently approved therapies either additively or synergistically. Thus, the study of combination therapy against multiple targets may be critically important to achieve more impact against lethal forms of prostate cancer resistant to all approved current therapies.


Subject(s)
Cell Transformation, Neoplastic/genetics , Cell Transformation, Neoplastic/metabolism , Disease Susceptibility , Prostatic Neoplasms/etiology , Prostatic Neoplasms/metabolism , Adaptor Proteins, Signal Transducing/genetics , Adaptor Proteins, Signal Transducing/metabolism , Animals , Autophagy/genetics , Combined Modality Therapy , Disease Progression , Epigenesis, Genetic , Gene Expression Regulation, Neoplastic , Humans , Male , Neoplastic Stem Cells/metabolism , Neoplastic Stem Cells/pathology , Prostatic Neoplasms/pathology , Prostatic Neoplasms/therapy , Transcription Factors/genetics , Transcription Factors/metabolism , YAP-Signaling Proteins
5.
J Pharm Pharmacol ; 71(3): 306-315, 2019 Mar.
Article in English | MEDLINE | ID: mdl-30362115

ABSTRACT

OBJECTIVES: Drug combination in cancer therapy aims to achieve synergistic therapeutic effect, reduced drug dosage, reduced drug toxicity and minimizes or delays the induction of drug resistance. In the present study, we investigated the anticancer effects of the combination of two metabolic modulators, dichloroacetate (DCA) and bacillus caldovelox arginase (BCA) (or pegyated human arginase (HA)). METHODS: The combination treatments were evaluated in MCF-7 and MDA-MB 231 cells as well as in MDA-MB 231 breast cancer xenograft model. KEY FINDINGS: Dichloroacetate and BCA combination exhibited anti-proliferative effects on MCF-7 cells, which were found to be synergistic. Analysis of the gene expression upon drug treatments revealed that the synergistic anti-proliferative effect on MCF-7 cells was possibly in part due to the activation of the p53 pathway. A similar synergistic anti-proliferative effect was observed in the combined use of DCA and HA on MCF-7 and MDA-MB231 cells, which was due to induction of cell cycle arrest at G2/M phase. Moreover, the combination enhanced anti-tumour activity in a MDA-MB 231 xenograft mouse model. CONCLUSIONS: Our results suggested that dichloroacetate and arginase combination exhibited enhanced anti-cancer effects in preclinical breast cancer models which may offer an additional treatment option for breast cancer.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/pharmacology , Arginase/pharmacology , Cell Proliferation/drug effects , Dichloroacetic Acid/pharmacology , Triple Negative Breast Neoplasms/drug therapy , Animals , Cell Cycle Checkpoints/drug effects , Cell Line, Tumor , Drug Therapy, Combination/methods , Female , G2 Phase Cell Cycle Checkpoints/drug effects , Humans , MCF-7 Cells , Mice , Mice, Inbred BALB C , Mice, Nude
6.
Eur J Cancer Prev ; 23(6): 550-9, 2014 Nov.
Article in English | MEDLINE | ID: mdl-25025584

ABSTRACT

The inexorable increase in the incidence of colorectal cancer has led to growing interest in its prevention by natural interventions. Thus, the present study was designed with the aim of delineating the antioxidative and antitumorigenic effects of synbiotics in experimental colon carcinogenesis. It was observed that administration of a synbiotic, before 1,2 dimethylhydrazine dihydrochloride (DMH)-induced colon carcinogenesis in Sprague-Dawley rats, led to increased body weight and growth rate, and decreased tumor incidence compared with the DMH-only-treated group of animals. Most notably, the level of malondialdehyde, a measure of lipid peroxidation, decreased, and levels of the antioxidants, glutathione reductase, superoxide dismutase, and glutathione peroxidase increased in animals in the Lactobacillus acidophilus+DMH, inulin+DMH, and synbiotic+DMH groups compared with DMH-only-treated animals. Histopathological observations of the colon also documented fewer dysplastic changes and increased the number of goblet cells in the probiotic-treated, prebiotic-treated, and synbiotic-treated animals compared with DMH-only-treated animals. Taken together, the present study shows that the use of synbiotics is a better prophylactic strategy than the use of probiotic and prebiotic alone because of the greater increase in antioxidants associated with the higher degree of attenuation of DMH-induced tumorigenesis.


Subject(s)
Carcinogenesis , Colonic Neoplasms/prevention & control , Inulin/pharmacology , Lacticaseibacillus rhamnosus/physiology , Lactobacillus acidophilus/physiology , Oxidative Stress , Synbiotics , 1,2-Dimethylhydrazine , Animals , Carcinogenesis/drug effects , Carcinogens , Colon/drug effects , Colon/metabolism , Colonic Neoplasms/chemically induced , Male , Oxidative Stress/drug effects , Rats , Rats, Sprague-Dawley , Time Factors
7.
Nutr Cancer ; 65(1): 84-91, 2013.
Article in English | MEDLINE | ID: mdl-23368917

ABSTRACT

Diet makes an important contribution to colorectal cancer (CRC) risk implying risks for CRC are potentially reducible. Therefore, the probiotics have been suggested as the prophylactic measure in colon cancer. In this study, different probiotics were used to compare their protective potential against 1,2 dimethylhydrazine dihydrochloride (DMH)-induced chemical colon carcinogenesis in Sprague Dawley rats. Animals belonging to different probiotic groups were fed orally with 1 × 10(9) lactobacilli daily for 1 week, and then a weekly injection of DMH was given intraperitoneally for 6 wks with daily administration of probiotic. Lactobacillus GG and L.acidophilus + DMH-treated animals had maximum percent reduction in ACF counts. A significant decrease (P < 0.05) in fecal nitroreductase activity was observed in L.casei + DMH and L.plantarum + DMH-treated rats whereas ß-glucuronidase activity decreased in L.GG + DMH and L.acidophilus + DMH-treated rats. Animals treated with Bifidobacterium bifidum + DMH had significant decreased ß-glucosidase activity. However, not much difference was observed in the colon morphology of animals belonging to various probiotic + DMH-treated rats compared with DMH-treated alone. The results indicated that probiotics, L.GG, and L.acidophilus can be used as the better prophylactic agents for experimental colon carcinogenesis.


Subject(s)
Aberrant Crypt Foci/diet therapy , Colonic Neoplasms/prevention & control , Feces/enzymology , Lacticaseibacillus rhamnosus , Lactobacillus acidophilus , Probiotics/pharmacology , 1,2-Dimethylhydrazine/toxicity , Aberrant Crypt Foci/chemically induced , Aberrant Crypt Foci/pathology , Animals , Body Weight/drug effects , Colonic Neoplasms/chemically induced , Colonic Neoplasms/pathology , Glucuronidase/metabolism , Nitroreductases/metabolism , Precancerous Conditions/chemically induced , Precancerous Conditions/pathology , Precancerous Conditions/prevention & control , Rats , Rats, Sprague-Dawley
8.
ISRN Parasitol ; 2013: 762638, 2013.
Article in English | MEDLINE | ID: mdl-27335861

ABSTRACT

Malnutrition reduces the host immunity and enhances the host susceptibility to various diseases. The present study describes the effect of oral administration of probiotic Lactobacillus casei to malnourished-Giardia-infected BALB/c mice with respect to surface alterations and brush border membrane enzyme activity of the small intestine. It was observed that probiotic feeding either prior to or simultaneously with Giardia infection to malnourished mice led to significantly enhanced activity of disaccharidases compared with malnourished and Giardia-infected mice. Scanning electron microscopy also revealed less mucosal damage in the villi of small intestine of probiotic-fed malnourished-Giardia-infected mice compared with completely damaged, mummified, or blunted villi of malnourished-Giardia-infected mice. The findings indicate that probiotics can be used as the prophylactic candidate in abrogating the gut and intestinal dissacharidases anamolies in malnourished hosts suffering from the intestinal diseases.

9.
Antonie Van Leeuwenhoek ; 102(1): 61-72, 2012 Jun.
Article in English | MEDLINE | ID: mdl-22382675

ABSTRACT

The present study describes the in vivo ameliorating effect of Lactobacillus casei supplementation in renourished Giardia intestinalis infected BALB/c mice. It was observed that daily administration of probiotic 7 days prior to Giardia-infection to renourished mice, efficiently reduced the excretion of Giardia cysts and trophozoite counts, along with significant increased fecal lactobacilli counts compared with Giardia-infected mice. It was also observed that oral feeding of probiotic to renourished-Giardia-infected mice abrogated all the anthropometric and biochemical anomalies. Histologically, morphological and cellular alteration of microvillus membrane integrity revealed that probiotic administration further ameliorated the mucosal damage in renourished-probiotic-Giardia-infected mice compared to severe microvillus atrophy, oedematous, vacuolated epithelial cells and ileitis in renourished-Giardia and Giardia-infected mice. Thus, it is suggested that probiotic used as the functional food helps in restoration of anthropometric, biochemical alterations and atrophied gut by enhancing the goblet cells and reducing the giardiasis.


Subject(s)
Diet/methods , Giardia lamblia/pathogenicity , Giardiasis/pathology , Lacticaseibacillus casei/growth & development , Probiotics/administration & dosage , Animals , Biometry , Dietary Supplements , Intestinal Mucosa/pathology , Mice , Mice, Inbred BALB C , Microvilli/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...